The historical rank and industry rank for Stoke Therapeutics's FCF Margin % or its related term are showing as below:
STOK'
s FCF Margin % Range Over the Past 10 Years
Min: -941.72 Med: -263.49 Max: 24.35
Current: -460.4
During the past 9 years, the highest FCF Margin % of Stoke Therapeutics was 24.35%. The lowest was -941.72%. And the median was -263.49%.
STOK's FCF Margin % is ranked worse than 71.12% of 959
companies
in the Biotechnology industry
Industry Median: -84.65
vs STOK: -460.40
Stoke Therapeutics FCF Margin % Related Terms
Stoke Therapeutics FCF Margin % Historical Data
* Premium members only.
The historical data trend for Stoke Therapeutics's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Stoke Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stoke Therapeutics FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Stoke Therapeutics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Stoke Therapeutics's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stoke Therapeutics (STOK) has a FCF Margin % of -978.25% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Stoke Therapeutics and its competitors. According to the industry distribution chart, Stoke Therapeutics ranks #682 out of 959 companies in the Biotechnology industry, placing it in the top 71.1%.
Is Stoke Therapeutics' FCF Margin % too high?
Stoke Therapeutics' current FCF Margin % is -978.25%. Based on the distribution chart, Stoke Therapeutics ranks #682 out of 959 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Stoke Therapeutics has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Stoke Therapeutics' FCF Margin % compare to SION and RXRX?
According to the Biotechnology industry distribution chart, Stoke Therapeutics ranks #682 out of 959 companies for FCF Margin %. This places Stoke Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Stoke Therapeutics and its competitors. Stoke Therapeutics's current FCF Margin % is -978.25%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stoke Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Stoke Therapeutics (STOK) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.16, compared to a current price of $31.90 — trading 214% above its estimated fair value. The current FCF Margin % is -978.25%. Stoke Therapeutics' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Stoke Therapeutics (STOK), the current FCF Margin % is -978.25% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stoke Therapeutics (STOK) Overvalued in 2026?
Based on GuruFocus' analysis, Stoke Therapeutics stock appears to be overvalued.
The current stock price of $31.90 is trading 214% above its estimated GF Value™ of $10.16.
GuruFocus considers Stoke Therapeutics to be Significantly Overvalued.
Key valuation signals for STOK:
FCF Margin %: -978.25%
GF Value™: $10.16 vs. price of $31.90 (214% above fair value)
No single metric tells the full story. See the STOK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
45GF Score
Get the complete analysis for STOK
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STOK has been successfully added to your 
